Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC (NCT03629925), a randomized phase 3 study. The primary outcome is PFS(Progression Free Survival).

2. Clinical Question

ORIENT-12 asked whether adding sintilimab to gemcitabine plus platinum chemotherapy was associated with different outcomes from adding placebo to that chemotherapy in patients with advanced or metastatic squamous non-small-cell lung cancer receiving first-line treatment. The central endpoint was progression-free survival (PFS), measured from randomization until the first documented progression of disease or death from any cause, whichever came first.

The registry record describes a randomized, double-blind, parallel-group phase III study. One group received sintilimab with gemcitabine and cisplatin or carboplatin; the other received placebo with gemcitabine and cisplatin or carboplatin. The posted PFS results are medians with 95% confidence intervals, based on assessment according to RECIST 1.1 by a blinded independent radiologic review committee. They report a median of 5.5 months (95% CI 4.9 to 6.8) for the sintilimab combination and 4.9 months (95% CI 4.8 to 5.0) for the placebo combination.

The statistical question is how to interpret those arm-specific estimates and their precision, particularly because a sponsor-reported between-group hazard ratio or other inferential comparison for PFS is not reported in the registry record. The posted objective response rate and disease control rate provide additional, binary summaries of tumor response, while overall survival, time to response, and duration of response are listed as secondary outcomes but their results are not included in the posted outcome measures.

3. Trial Design

The registry describes ORIENT-12 (NCT03629925) as a randomized, double-blind, parallel-group phase III study sponsored by Innovent Biologics (Suzhou) Co. Ltd. It enrolled 357 participants. The study began on 2018-09-28, reached primary completion on 2020-03-25, and is listed as completed.

The randomized groups differed by the addition of sintilimab or placebo to gemcitabine plus platinum chemotherapy. The platinum option could be cisplatin or carboplatin in either group. The registry record lists 179 participants in the sintilimab combination group and 178 in the placebo combination group for the posted primary endpoint. The design is described as double-blind, but the registry record does not report further details about who was masked or how masking was maintained.

The primary endpoint was PFS assessed according to RECIST 1.1 by a blinded independent radiologic review committee. The stated observation period was through the database cutoff date of 25 March 2020, up to approximately 18 months. The registry also lists overall survival, objective response rate, time to response, disease control rate, and duration of response as secondary outcomes. Results are posted for objective response rate and disease control rate in addition to PFS; the other listed secondary outcomes do not have results described in the posted outcome measures.

Some elements needed to evaluate the design fully are not reported in the registry record. These include the eligibility criteria in detail, the randomization procedure and any stratification factors, the planned sample-size justification, the analysis populations, the handling of missing or censored observations, and the statistical analysis plan. The sample-size illustrations associated with the posted binary outcomes are based on observed effects and are not the trial's own design calculations.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as PFS(Progression Free Survival), measured over Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months).

PFS measures the time from randomization until the first documented progression of disease or death from any cause, whichever occurs first. It is a time-to-event endpoint: each participant contributes information about how long they remained alive without documented progression, while participants without an observed event by the cutoff may contribute censored follow-up. The registry record does not report the censoring rules used in the analysis.

Progression was assessed using RECIST 1.1. The registry description defines progression of a target lesion as an increase of at least 20% in the sum of target-lesion diameters, together with an absolute increase of at least 5 mm. The appearance of one or more new lesions also counted as progression. PFS was assessed by a blinded independent radiologic review committee.

This endpoint is used because it combines progression and death into a measure of time free from either event. It can therefore describe the timing of disease worsening or death without requiring every participant to have died during follow-up. As a general statistical point, a median is the time by which half of the estimated event-time distribution has had an event; it does not describe the outcome of every participant. The confidence interval communicates uncertainty around the median estimate. The registry record reports arm-specific medians and intervals, but does not report a sponsor's between-group PFS hazard ratio or a formal comparison of the PFS distributions.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The main statistical distinction is between an arm-specific summary and a comparison of randomized groups. The primary results report a median PFS for each group, with a 95% confidence interval for each median. They do not report a hazard ratio or a confidence interval for a between-group contrast. For the secondary binary outcomes, the posted arm percentages are accompanied by intervals, and separate unadjusted comparisons have been recalculated from the posted counts.

What does a median PFS describe?

For a time-to-event outcome, the median is the time at which the estimated event-free proportion reaches one half. In this trial, the event is documented progression or death, whichever occurs first. A median is a compact summary of the time-to-event distribution, but it does not show the whole distribution. Two groups can have similar medians while differing at other times, or have different medians without the difference being estimated precisely. A median also does not indicate how many participants were still under observation at each time unless that information is reported separately.

Participants who have not had a documented progression or death by the analysis cutoff may be censored rather than counted as having an event. Censoring allows their observed follow-up to contribute information up to the time they were last known to be event-free. Interpretation depends on how censoring is defined and handled. The censoring rules and details of the analysis population are not reported in the registry record, so those aspects cannot be assessed from the posted median results alone.

How should the confidence intervals be read?

A confidence interval describes the uncertainty of an estimate under the method used to calculate it. The PFS intervals are attached to the medians for each arm; they are not intervals for a difference between those medians. Comparing whether two arm-specific intervals overlap is not a formal test of the treatment contrast. The registry record does not report the time-to-event comparison needed to make that inference, such as a sponsor-reported hazard ratio with its confidence interval.

For the binary secondary outcomes, the posted confidence intervals describe uncertainty around the response or disease-control percentage in each arm. The recalculated risk-difference intervals instead describe uncertainty around the difference in proportions, using the unadjusted comparison. An interval that includes zero means the recalculated interval is compatible with no risk difference under its method; it does not demonstrate equivalence, and it does not establish that the true difference is zero.

What is an unadjusted recalculation?

The objective response and disease control comparisons are labeled as recalculated because they are simple, unadjusted analyses using the posted summary counts. They are not listed as reported sponsor analyses. The unadjusted P values are 0.073 for objective response rate and 0.15 for disease control rate. They do not account for any multiplicity across outcomes, and the registry record does not report a prespecified analysis plan for these comparisons. These results are therefore best read as exploratory statistical summaries of the posted counts, not as a replacement for the trial's own analysis.

The ORR percentages are reported with more decimal places in their confidence limits than the rounded arm percentages. The recalculated comparisons use the posted counts and denominators, rather than treating the rounded arm percentages as exact. The risk difference is reported on the proportion scale. No transformation of that value into percentage points is needed to interpret its direction and uncertainty.

Why do time-to-event methods differ from binary comparisons?

A time-to-event analysis uses both whether an event occurred and when it occurred, while accounting for participants who have incomplete follow-up at the cutoff. A binary outcome reduces the observation to whether a response or disease control was recorded within the outcome assessment period. These methods answer related but distinct questions. A response rate does not summarize how long the response lasted, and PFS includes progression or death rather than response alone.

In time-to-event analysis, a hazard ratio can summarize the relative event rates over follow-up under the model and assumptions used. It is not a ratio of medians and cannot be recovered from the two posted median values. The registry record does not report a sponsor PFS hazard ratio, its confidence interval, or a reported analysis for this endpoint. The recalculated secondary outcome comparisons do not fill that gap.

Why does over-dispersion matter?

General statistical explanation: over-dispersion occurs when observed variation is greater than a model assumes. If a model treats outcomes as less variable than they are, standard errors may be too small and confidence intervals or tests may appear more precise than warranted. This concept is relevant when selecting models for some count or clustered outcomes, but the registry record does not report that over-dispersion was assessed or that a model of this type was used for the posted endpoints. It should not be assumed to describe the analysis in ORIENT-12.

The planning illustrations for the binary endpoints are explicitly based on the observed effect, equal allocation, a two-sided significance level of 0.05, and a normal approximation. Their entries describe participants per arm for 80% or 90% power under the stated fraction of the observed effect. They are planning illustrations, not observed power, and not the trial's sample-size justification. The registry record does not report the trial's original sample-size assumptions or justification.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists several secondary outcomes alongside the primary PFS endpoint. It does not report how the trial handled multiplicity, such as whether testing across outcomes was controlled, whether endpoints were evaluated in a prespecified sequence, or whether any secondary analyses were designated as confirmatory. Without that information, the unadjusted P values for the posted binary outcomes cannot be interpreted as multiplicity-adjusted evidence.

Missing-data and censoring methods are also not reported in the registry record. For PFS, the record does not specify how participants without a documented progression or death by the cutoff were censored, how incomplete assessments were handled, or how missing imaging information affected endpoint status. The record does not describe missing-data procedures for the binary response outcomes either. These details matter because incomplete observations can affect estimates and their uncertainty.

The analysis populations are not reported in the registry record. It is therefore not possible to determine from these results whether the posted analyses used all randomized participants, a population meeting other eligibility conditions, or another defined group. The record also does not report the statistical analysis plan, interim analyses, or the primary endpoint's sponsor-reported inferential comparison. No additional protocol details should be inferred from the fact that the study is described as randomized and double-blind.

The sample-size illustrations associated with the binary comparisons are not the original design justification. They use the observed effect and specified planning assumptions, and are illustrative rather than a record of the trial's planned power calculation. The trial's own sample-size justification is not reported in the registry record. These omissions limit assessment of how the posted analyses relate to prespecified hypotheses and planned decision criteria.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: platelet count decreased (18.0%), pneumonia (12.3%), white blood cell count decreased (4.5%), haemoptysis (4.5%), anaemia (3.4%).

The adverse-event summary lists serious adverse events affecting 90 of 179 participants in the sintilimab combination group and 80 of 178 participants in the placebo combination group. It also records participants in the category labelled other adverse events as 179 of 179 and 178 of 178, respectively. Deaths are listed as 65 and 71, respectively. The registry record does not provide enough detail in these figures alone to establish the timing, cause, attribution, or relationship of individual events to study treatment.

The most frequent serious adverse-event terms listed are platelet count decreased (18.0%), pneumonia (12.3%), white blood cell count decreased (4.5%), haemoptysis (4.5%), anaemia (3.4%), and neutrophil count decreased (2.8%). These term-specific percentages are descriptive registry summaries; they do not by themselves compare the overall safety profiles or establish causality. The record does not report additional details about event severity, exposure time, statistical comparisons, or how events were attributed.

Safety counts should be interpreted in the context of the groups and definitions used in the registry record. A count difference is not, by itself, a causal estimate or a complete account of benefit and risk. No medical conclusion follows from these figures alone.

12. What the Result Does, and Does Not, Mean

The posted results describe outcomes in two randomized groups receiving the same chemotherapy backbone, with sintilimab in one group and placebo in the other. For PFS, the registry reports an arm-specific median and 95% confidence interval for each group. The estimates are useful summaries of the observed time-to-event data through the stated cutoff, but they do not supply a formal between-group PFS estimate. The registry record does not report a sponsor hazard ratio, confidence interval for the treatment contrast, or P value for the primary endpoint.

The binary secondary outcomes show posted percentages and recalculated unadjusted comparisons. Those comparisons are based on summary counts and do not account for multiplicity. Their uncertainty should be considered alongside their descriptive direction, rather than treating the point estimates or P values as conclusive. The record does not report the results for all of the listed secondary endpoints, so the posted secondary findings do not provide a complete account of every planned outcome.

These results do not establish that the groups are equivalent, nor do the differences in arm-level estimates alone establish a causal treatment effect of a particular size. Randomization is a design feature intended to support fair comparisons, but interpreting an effect requires the prespecified analysis, its uncertainty, and details such as the analysis population and handling of censoring and missing observations. Several of those details are not reported in the registry record.

The findings are limited to the population, treatments, endpoint definitions, assessment process, and follow-up described in the record. The posted PFS results cover the period through the database cutoff date of 25 March 2020, up to approximately 18 months. They do not, on their own, answer questions about outcomes beyond that follow-up or about secondary outcomes for which results are not reported. No medical advice or treatment recommendation follows from these registry summaries.

13. Why This Trial Matters Statistically

ORIENT-12 illustrates why the form of an endpoint matters when reading a clinical trial result. PFS is a time-to-event outcome, but the posted primary results consist of arm-specific medians and confidence intervals. A median gives a compact view of the event-time distribution; it is not itself a treatment contrast and cannot be used to reconstruct a hazard ratio. The absence of a reported primary comparison limits the inferential conclusions that can be drawn from the registry record.

The secondary binary outcomes demonstrate a related issue. Arm percentages can be compared descriptively, while a risk difference and its interval provide a direct unadjusted summary of the between-group contrast. In this record, those comparisons are recalculated from the posted summary counts rather than presented as sponsor analyses. Their intervals include zero, and no multiplicity strategy is reported. Distinguishing descriptive patterns from confirmatory inference is essential when several outcomes are available.

The record also shows why transparency about analysis decisions matters. Interpretation depends not only on the endpoint values, but also on the planned sample-size rationale, analysis populations, missing-data handling, censoring rules, and any interim or multiplicity procedures. These details are not reported in the registry record. The sample-size illustrations based on observed effects do not replace the original design justification and are not observed power.

For clinical researchers and statisticians, the central lesson is to align claims with the level of evidence actually posted: arm summaries support description; fully specified comparisons support inference. Keeping those roles separate prevents a difference in point estimates from being overstated and prevents an inconclusive interval from being mistaken for evidence of equivalence.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for statistical interpretation is that the registry record reports median PFS by arm but not a sponsor-reported hazard ratio, treatment-contrast confidence interval, or P value. The record itself notes that values are missing or not estimable for a two-arm comparison for this median-time endpoint. Thus, the primary endpoint cannot be evaluated using a reported formal comparison in this record.

Important methodological details are not reported in the registry record: the analysis populations, censoring rules, handling of missing endpoint assessments, randomization and stratification procedures, statistical analysis plan, multiplicity approach, interim analyses, and the trial's sample-size justification. Without these details, it is difficult to assess how closely the posted results follow prespecified methods or how sensitive they may be to missing follow-up and analysis choices.

Only objective response rate and disease control rate are posted among the listed secondary outcomes in the results. Overall survival, time to response, and duration of response are listed but their results are not reported in the registry record. The available secondary comparisons are unadjusted recalculations from summary counts, not reported sponsor analyses, and no multiplicity adjustment is reported.

The follow-up is tied to the database cutoff date of 25 March 2020, up to approximately 18 months. These results therefore do not describe outcomes beyond that stated period. Safety information is also limited to the posted counts and selected serious-event terms; the record does not give enough detail about event attribution, exposure time, or comparative analysis to support a comprehensive safety assessment.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC — NCT03629925.
• Registry record last updated 2023-02-28; status last verified 2023-02.
• Results first posted 2021-04-01.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03629925, ORIENT-12, is a completed randomized, double-blind, parallel-group phase III study sponsored by Innovent Biologics (Suzhou) Co. Ltd. It enrolled 357 participants with advanced or metastatic squamous NSCLC and compared sintilimab plus gemcitabine and cisplatin or carboplatin with placebo plus the same chemotherapy. The study began on 2018-09-28 and reached primary completion on 2020-03-25.

The primary outcome was PFS assessed by a blinded independent radiologic review committee according to RECIST 1.1. The registry reports median PFS and 95% confidence intervals by arm through the database cutoff date of 25 March 2020, up to approximately 18 months. It also posts objective response rate and disease control rate results. Results for the other listed secondary outcomes, including overall survival, time to response, and duration of response, are not reported in the registry record.